blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).

blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition

TB drugs IV on day 1 for calculation of bioavailability while fasting or fed

pharmacokinetics (AUC0-8, Cmax, and Tmax); comparison between TB patients who take HRZE concomitant with food and TB patients who take HRZE concomitant without food, weeks 1 and 8 of treatment

PK curves from venous blood specimens sampled from indwelling venous catheter

tolerance - acceptance; vomiting, refusal

Parameters which may influence the pharmacokinetics of HRZE will be measured at start and end of the study.

• BMI, i.e. body weight and length
• age
• gender
• ethnicity
• co-morbidity, for instance HIV/AIDS, diabetes (only at start)
• co-medication: especially HIV medication, prednisolone (may lower INH concentration), antacids (may lower absorption of HRE concentration)
• chemistry: liver function, renal function, hemoglobulin, albumin, bilirubin
• pharmacogenetics